ERBB2 and breast carcinoma: Spring LM, Han H, Liu MC, Hamilton E, Irie H, Santa-Maria CA, et al. Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer.